alprenolol has been researched along with sq-11725 in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (18.52) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (51.85) | 29.6817 |
| 2010's | 8 (29.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; el Tayar, N; Testa, B; Van de Waterbeemd, H | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Baker, JG | 1 |
| Artursson, P; Bergström, CA; Matsson, P; Nagahara, N; Norinder, U; Tavelin, S | 1 |
| Akamatsu, M; Fujikawa, M; Nakao, K; Shimizu, R | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bard, B; Carrupt, PA; Martel, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Antonsson, M; Bengtsson, O; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Jerndal, G; Wan, H; Winiwarter, S | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Akamatsu, M | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Fishbein, L; Jackson, CD | 1 |
| Hashimoto, H; Nakashima, M; Oguro, K; Sogabe, K; Takiguchi, Y | 1 |
| Borer, JS; Moses, JW | 1 |
| Hashimoto, K; Kanazawa, Y; O'Hara, N; Ono, H | 1 |
| Horinouchi, T; Koike, K | 1 |
| Hirouchi, M; Katsura, M; Ohkuma, S; Shibasaki, M; Tsujimura, A | 1 |
| Bond, RA; Bouvier, M; Forkuo, GS; Joshi, R; Knoll, BJ; Leff, P; Parra, S; Thanawala, VJ; Valdez, DJ | 1 |
3 review(s) available for alprenolol and sq-11725
| Article | Year |
|---|---|
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Models, Molecular; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1988 |
A toxicological review of beta-adrenergic blockers.
Topics: Acebutolol; Adrenergic beta-Antagonists; Alprenolol; Animals; Atenolol; Cocarcinogenesis; Ethanolamines; Female; Kinetics; Labetalol; Lethal Dose 50; Male; Metoprolol; Mice; Mutagens; Nadolol; Neoplasms, Experimental; Oxprenolol; Pindolol; Practolol; Propanolamines; Propranolol; Rats; Sotalol; Timolol | 1986 |
Beta-adrenergic antagonists in the treatment of patients with heart disease.
Topics: Acebutolol; Adrenergic beta-Agonists; Alprenolol; Animals; Arrhythmias, Cardiac; Bronchial Spasm; Cardiomyopathy, Hypertrophic; Coronary Disease; Female; Heart Diseases; Heart Failure; Humans; Hypertension; Metoprolol; Mitral Valve Prolapse; Mitral Valve Stenosis; Nadolol; Nervous System Diseases; Pindolol; Pregnancy; Pregnancy Complications, Cardiovascular; Propanolamines; Propranolol; Receptors, Adrenergic, beta; Structure-Activity Relationship; Timolol | 1981 |
24 other study(ies) available for alprenolol and sq-11725
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Algorithms; Animals; Cell Line; CHO Cells; Cricetinae; Dioxoles; Humans; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Adrenergic, beta-3 | 2005 |
Exploring the role of different drug transport routes in permeability screening.
Topics: Administration, Oral; Biological Transport; Caco-2 Cells; Cell Line; Humans; Intestinal Absorption; Intestinal Mucosa; Intestine, Small; Membranes, Artificial; Models, Biological; Molecular Conformation; Monte Carlo Method; Permeability; Pharmaceutical Preparations; Pharmacokinetics | 2005 |
QSAR study on permeability of hydrophobic compounds with artificial membranes.
Topics: Biological Transport; Caco-2 Cells; Drug Evaluation, Preclinical; Humans; Hydrophobic and Hydrophilic Interactions; Membranes, Artificial; Permeability; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
Topics: Chemistry, Pharmaceutical; Chromatography; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Pharmaceutical Preparations; Solubility; Technology, Pharmaceutical | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
Topics: Animals; Blood-Brain Barrier; Brain; Extracellular Fluid; Humans; Linear Models; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Importance of physicochemical properties for the design of new pesticides.
Topics: Anabasine; Animals; Biological Availability; Cell Membrane Permeability; Chemical Phenomena; Drug Design; Humans; Imidazoles; Insecticides; Neonicotinoids; Nitro Compounds; Pesticides; Quantitative Structure-Activity Relationship; Receptors, Nicotinic | 2011 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Anti-arrhythmic effect of nadolol in experimental arrhythmias: comparison with propranolol and alprenolol.
Topics: Alprenolol; Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Dogs; Epinephrine; Female; Halothane; Male; Nadolol; Ouabain; Propanolamines; Propranolol | 1985 |
Estimation of cardiodepressant potency of nadolol, alprenolol, propranolol and pindolol, beta-blocking agents, in heart-lung preparation and blood-perfused excised papillary muscle preparation of the dog.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Anti-Arrhythmia Agents; Dogs; Heart; Heart Rate; In Vitro Techniques; Myocardial Contraction; Nadolol; Papillary Muscles; Pindolol; Propanolamines; Propranolol | 1984 |
Functional properties of atypical beta-adrenoceptors on the guinea pig duodenum.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Alprenolol; Animals; Bupranolol; Carteolol; Clenbuterol; Dobutamine; Dopamine; Dose-Response Relationship, Drug; Duodenum; Epinephrine; Ethanolamines; Fenoterol; Guinea Pigs; In Vitro Techniques; Isoproterenol; Male; Muscle Relaxation; Nadolol; Norepinephrine; Phenylephrine; Pindolol; Propanolamines; Propranolol; Receptors, Adrenergic, beta; Stereoisomerism | 2001 |
Expression of beta-adrenergic receptor up-regulation is mediated by two different processes.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Blotting, Western; Cells, Cultured; Cerebral Cortex; Cycloheximide; Dose-Response Relationship, Drug; Drug Interactions; Embryo, Mammalian; Mice; Nadolol; Neurons; Propanolamines; Protein Binding; Protein Synthesis Inhibitors; Receptors, Adrenergic, beta; RNA, Messenger; Signal Transduction; Time Factors; Tritium; Up-Regulation | 2006 |
β-Blockers have differential effects on the murine asthma phenotype.
Topics: Adrenergic beta-Antagonists; Allergens; Alprenolol; Animals; Asthma; Bronchoalveolar Lavage Fluid; Carbazoles; Carvedilol; Cell Count; Epinephrine; Female; Male; Mice, Knockout; Models, Biological; Mucins; Nadolol; Ovalbumin; Phenotype; Propanolamines; Propranolol | 2015 |